The COVID-19 vaccine developed by AstraZeneca PLC and Oxford University showed 74% efficacy at preventing symptomatic illness in a large, late-stage trial conducted in the U.S., Chile and Peru, according to data published in the New England Journal Of Medicine on Thursday.
read more